An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

NCT03041909 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
5
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Global Blood Therapeutics